Upgrade to SI Premium - Free Trial

Summit Therapeutics (SMMT) Reiterated at Buy by Stifel on HARMONi-6 'Win'

June 1, 2026 7:41 AM
Stifel analyst Dara Azar reiterated a Buy rating and $45.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments